News coverage about Mallinckrodt PLC (NYSE:MNK) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mallinckrodt PLC earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.9900480467373 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Analyst: Mallinckrodt Stock Is Undervalued – Benzinga (benzinga.com)
- Mallinckrodt Plc (MNK) Volume Trending Higher – Evergreen Caller (evergreencaller.com)
- Mallinckrodt Plc (MNK) Sees The Tape Move Mid-Market – Evergreen Caller (evergreencaller.com)
- Mallinckrodt: FDA Chief Comments Are Another Negative – Seeking Alpha (seekingalpha.com)
Mallinckrodt PLC (MNK) opened at 36.36 on Friday. The stock’s 50 day moving average is $42.76 and its 200 day moving average is $45.25. Mallinckrodt PLC has a 52 week low of $35.04 and a 52 week high of $85.83. The firm’s market cap is $3.53 billion.
Mallinckrodt PLC (NYSE:MNK) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $1.85 EPS for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.12. The business had revenue of $824.50 million for the quarter, compared to analyst estimates of $829.56 million. Mallinckrodt PLC had a net margin of 12.64% and a return on equity of 15.28%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.03 earnings per share. Equities research analysts expect that Mallinckrodt PLC will post $7.46 EPS for the current year.
Several equities research analysts recently commented on the stock. Oppenheimer Holdings, Inc. set a $70.00 price target on shares of Mallinckrodt PLC and gave the company a “buy” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded shares of Mallinckrodt PLC from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. BMO Capital Markets restated a “buy” rating and issued a $69.00 price target on shares of Mallinckrodt PLC in a research report on Friday, July 28th. Canaccord Genuity reduced their price target on shares of Mallinckrodt PLC from $91.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, May 9th. Finally, Piper Jaffray Companies set a $85.00 price target on shares of Mallinckrodt PLC and gave the company a “buy” rating in a research report on Sunday, July 16th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $71.25.
In other Mallinckrodt PLC news, VP Steven J. Romano acquired 1,000 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were acquired at an average price of $39.88 per share, with a total value of $39,880.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Coleman N. Lannum III acquired 1,350 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was acquired at an average cost of $42.89 per share, for a total transaction of $57,901.50. Following the transaction, the vice president now owns 30,955 shares of the company’s stock, valued at $1,327,659.95. The disclosure for this purchase can be found here. In the last three months, insiders bought 3,850 shares of company stock worth $157,687. 0.77% of the stock is currently owned by insiders.
About Mallinckrodt PLC
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
What are top analysts saying about Mallinckrodt PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mallinckrodt PLC and related companies.